moonpixlar.pw
Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies
The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing…